Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cbcc Global Research, Inc. at Comprehensive Blood and Cancer Center
Bakersfield, California, United States
- St. Joseph Heritage Healthcare
Fullerton, California, United States
- Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
- Orlando Health, Inc. D/b/a Orlando Health Uf Health Center
Orlando, Florida, United States
- Ft. Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana, United States
- Cancer Center of Kansas
Wichita, Kansas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2018
- Primary completion
- 1 Oct 2026
- Completion
- 1 Oct 2027
- Last update posted
- 10 Nov 2025
- Registered enrollment
- 35
- Registry id
- NCT03672773
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.